



**Grant Number:** 1R41CA183399-01A1  
**FAIN:** R41CA183399

**Principal Investigator(s):**  
Ruben Rene Gonzalez-Perez, PHD

**Project Title:** Novel adjuvant therapy for triple negative breast cancer

Lillard, James  
President & CEO  
Jyant, Inc.  
3393 Raes Creek Road  
Marietta, GA 300085702

**Award e-mailed to:** mwilliams@neo-bizsolutions.com

**Period Of Performance:**

**Budget Period:** 04/01/2015 – 03/31/2016

**Project Period:** 04/01/2015 – 03/31/2016

Dear Business Official:

The National Institutes of Health hereby awards a grant in the amount of \$225,000 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to JYANT Technologies, Inc. in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 15 USC 638 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the "Terms and Conditions" is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number R41CA183399. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

Alice Chi Wong  
Grants Management Officer  
NATIONAL CANCER INSTITUTE



REPLY TO  
ATTENTION OF

**DEPARTMENT OF THE ARMY**  
**US ARMY MEDICAL RESEARCH ACQUISITION ACTIVITY**  
**820 CHANDLER STREET**  
**FORT DETRICK MD 21702-5014**

May 14, 2013

Business Operations Division

Ruben Rene Gonzalez-Perez  
Morehouse School of Medicine  
Department of Microbiology, Biochemistry, and Immunology  
720 Westview Drive SW  
Atlanta, GA 30310-1495  
rgonzalez@msm.edu

RE: BC123427 - "Targeting Breast Cancer Stem Cells in Triple-Negative Breast Cancer"

STATUS: RECOMMENDED FOR FUNDING

Dear Ruben Rene Gonzalez-Perez:

Congratulations! On behalf of the Department of Defense (DoD) office of the Congressionally Directed Medical Research Programs (CDMRP), I am pleased to inform you that the Fiscal Year 2012 (FY12) Breast Cancer Research Program (BCRP) Idea Award application you submitted was recommended for funding. Funding recommendations were made at a second-tier, programmatic review meeting based on program goals and scientific merit. Please note that awards are subject to negotiations and availability of funds. Additional information on the review process is available in the information paper posted under your eReceipt account.

Additional documentation is needed to start the award process. Your timely submission of all applicable documents in the appropriate formats will expedite this process and the release of funds. A CDMRP Science Officer, who will be your scientific and technical point of contact throughout the life of this award, may contact you for further information regarding various aspects of your application. For example, your Science Officer will contact you about Animal Use and Human Use documents that may be needed for your project. Together, you will set a target date for the submission of your complete animal use or human use appendix documents.

A Grants/Contract Specialist from the US Army Medical Research Acquisition Activity (USAMRAA) will contact the Business Official (person authorized to conduct negotiations) at your institution to begin award negotiations. All official negotiations of the budget, terms, and conditions of any resulting award will be limited to the Business Official of your institution and the USAMRAA Grants/Contract Specialist.

Your performance on any previous CDMRP awards will be considered during negotiations. You are advised to review your current and past awards to ensure that all required information has been submitted, including all technical reporting and regulatory oversight documents, as this may impact the negotiation and award process.

If you are withdrawing your application, please co-sign a letter of withdrawal with an administrator from the Sponsored Programs Office at your institution and upload it under the “Required Award Information” tab on the CDMRP eReceipt website (<https://cdmrp.org>).

To expedite the award process, please answer the post-submission questions found under the “Required Award Information” tab on the CDMRP eReceipt website (<https://cdmrp.org>). You and your institution are responsible for ensuring that there is no duplication of the science, budget, or level of effort in separately funded studies in which you were or currently are involved. If you received funding for any portion of this application from another source, or if any portion of the proposed work has already started, please indicate so under this tab.

After providing the information requested under the “Required Award Information” tab, upload or provide the following, for all sites where the DoD-funded work will be conducted, under the “Required Award Documents” tab by May 29, 2013:

- Facility Safety Assurance documents (required only if the institution is not listed as approved at: [https://mrmc.amedd.army.mil/assets/docs/sse/Facility\\_Safety\\_Plan\\_Approved\\_Institutions.pdf](https://mrmc.amedd.army.mil/assets/docs/sse/Facility_Safety_Plan_Approved_Institutions.pdf))
- Environmental Compliance documents
- Principal Investigator Safety Assurance documents
- Updated details on all existing and pending support for yourself and key personnel, including the title of the project, goals, specific aims/tasks, estimated start date and end date, level of effort (percentage or calendar months) in the project, and point of contact at the funding agency. Provide a cover letter signed by a sponsored programs official, certifying that this information is current and accurate, and addresses any scientific or financial overlap.

A copy of this notification is being made available to your institution’s Sponsored Programs Office.

Again, congratulations on the recommendation of your application for funding. The CDMRP staff and I look forward to working with you to realize the vision of the BCRP, and we encourage you to share the news of your success with your colleagues and the community. Please direct any questions to the CDMRP at [help@cdmrp.org](mailto:help@cdmrp.org) or 301-682-5507.

Sincerely,

Wendy A. Baker  
Grants Officer



### Morehouse School of Medicine/Tuskegee University/UAB Comprehensive Cancer Center Partnership

3 October 2014

Dear Chris Klug (Co-Leader)  
(Dr. Reuben Gonzalez-Perez, Contact-PI)

Congratulations, the Scientific Advisory Committee of the Morehouse School of Medicine/Tuskegee University/UAB Comprehensive Cancer Center Partnership has approved your collaborative proposal with Reuben Gonzalez-Perez, "Role of Leptin-Notch Axis in Pancreatic Cancer" for funding.

Final award of your project is contingent upon the receipt of documentation of any IRB, IACUC, and or any other institutional requirements in order to carry out your proposed research. In addition, you must submit a separate **Career Development and Mentoring plan, if you are a junior partner**. Upon receipt of applicable documentation, the program manager at UAB will distribute an award letter and the account number for your component of budget, i.e., for **\$5,000/year**. The lead PI at Morehouse School of Medicine (Dr. Lillard) will send a similar award letter for **\$110,000** to your collaborator (Dr. Gonzalez-Perez) at MSM. All pilot project investigators must provide the Partnership with written progress reports as outlined below.

#### Progress Review Process for Pilot Research Projects

A Scientific Review Committee (SRC) has been appointed by the Cancer Research Program Co-Leaders to review progress of the Pilot Research Projects. The review Process will consist of:

1. Six months – oral presentation to the Partnership Advisory Committee/SRC and other invited ad hoc reviewers. This provides an opportunity for critiques and course corrections of projects at an early point.
1. Nine months – one page progress report update.
2. One year – a full written report for submission to the SRC.
3. Progress reports should be submitted in NIH format. Prior to submission, all Progress Reports and manuscripts should be routed through Dr. Don Hill, the Partnership's Scientific Writer.

#### Criteria to be used include:

2. Satisfactory progress according to established time line;
3. Ability to identify research and administrative problems;
4. Continued application of appropriate scientific methods;
5. Approach and interim and final conclusions;
6. Scientific integrity;
7. Scientific publications; and
8. Progress towards overarching research agenda; and
9. Career Development.

Recommendation options, to be communicated to the PI (contact Co-Leader) and to the SRC and Program Advisory Committee, include:

1. Modify the project;
2. Recommend continuation as *pilot* research project;
3. Recommend attempt at transition to competitive peer-reviewed funding; or
4. Terminate

#### Career Development and Mentoring Plan (If Applicable)

Pursuant to the goals of the Partnership to foster and train young scientists, you must complete and submit a *Career Development and Mentoring Plan*. This plan should include a brief overview of your Career Development Plan and the following items should be addressed: A) Background B) Career Goals and Objectives C) Career Development and Training Activities and D) Training in the Responsible Conduct of Research

In order to assess the long-term value of programs such as this, if required, the Partnership will periodically request information on your research progress. Please provide the Partnership with copies of all publications and the abstracts from grant applications derived from work sponsored by the Partnership.

In compliance with the NIH Public Access Policy (<http://publicaccess.nih.gov/>), you must ensure that any peer-reviewed publications that result from this funding are included in PubMed Central. Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the NIH National Cancer Institute award number U54 CA118638 (MSM)/ U54 CA118623 (TU)/ or U54 CA118948 (UAB )."

Once again congratulations on your selection for this award. We look forward to working closely with you to ensure the success of your proposed project and to assist in any way that we can with your career development and your pursuit of research related to racial health disparities. If you have questions, please let Ms. Suzanne Byan-Parker or me know.

Sincerely,



Upender Manne, MS, PhD

Lead PI of the UAB Component of the Morehouse-Tuskegee-UAB Comprehensive Cancer Center Partnership

I accept this award and agree to the conditions and expectations outlined above in this letter.

---

Signature (Co-Leader)

---

Date

CC: Scientific Review Committee  
Edward E. Partridge, MD  
Isabel Scarinci, PhD, MPH  
Mona Fouad, MD, MPH  
Timothy Turner, PhD  
Roberta Troy, PhD  
James Lillard, PhD, MBA  
Donald Hill, PhD